Glucagon-like peptide-1 (GLP-1) compounds have emerged as a compelling therapeutic strategy for managing metabolic conditions. These naturally occurring hormones are secreted by the gut in response to meal intake, stimulating insulin secretion and suppressing glucagon output. GLP-1 derivatives demonstrate promising therapeutic efficacy in treating